Bill would allow the board to implement upper payment limits for prescription drug purchases and payer reimbursements if the state finds that certain drugs are ‘unaffordable.’
The Prescription Drug Affordability Board is working with a large list of ‘eligible’ prescription drugs that meet certain statutory or regulatory metrics that could indicate a drug is hard for Marylanders to afford.
Over the course of 2024, the board will gather data, manufacturer information and public testimonies that will inform its consideration of which drugs should undergo state cost reduction efforts.
Health care-focused organizations across the state are hopeful that the 2024 legislative session will be a year that reins in health costs and allows…
Ahead of a challenging budget year, Maryland lawmakers evaluated the potential costs and savings of expanding health care benefits to residents that do not…